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Abstract 39 
Acrylamide, a probable human carcinogen, is ubiquitously present in the human 40 
environment, with sources including heated starchy foods, coffee and cigarette smoke. 41 
Humans are also exposed to acrylamide occupationally. Acrylamide is genotoxic, inducing 42 
gene mutations and chromosomal aberrations in various experimental settings. Covalent 43 
haemoglobin adducts were reported in acrylamide-exposed humans and DNA adducts in 44 
experimental systems. The carcinogenicity of acrylamide has been attributed to the effects of 45 
glycidamide, its reactive and mutagenic metabolite capable of inducing rodent tumors at 46 
various anatomical sites. In order to characterize the pre-mutagenic DNA lesions and global 47 
mutation spectra induced by acrylamide and glycidamide, we combined DNA-adduct and 48 
whole-exome sequencing analyses in an established exposure-clonal immortalization 49 
system based on mouse embryonic fibroblasts. Sequencing and computational analysis 50 
revealed a unique mutational signature of glycidamide, characterized by predominant 51 
T:A>A:T transversions, followed by T:A>C:G and C:G>A:T mutations exhibiting specific 52 
trinucleotide contexts and significant transcription strand bias. Computational interrogation of 53 
human cancer genome sequencing data indicated that a combination of the glycidamide 54 
signature and an experimental benzo[a]pyrene signature are nearly equivalent to the 55 
COSMIC tobacco-smoking related signature 4 in lung adenocarcinomas and squamous cell 56 
carcinomas. We found a more variable relationship between the glycidamide- and 57 
benzo[a]pyrene-signatures and COSMIC signature 4 in liver cancer, indicating more 58 
complex exposures in the liver. Our study demonstrates that the controlled experimental 59 
characterization of specific genetic damage associated with glycidamide exposure facilitates 60 
identifying corresponding patterns in cancer genome data, thereby underscoring how 61 
mutation signature laboratory experimentation contributes to the elucidation of cancer 62 
causation. 63 
 64 
A 40-word summary  65 
Innovative experimental approaches identify a novel mutational signature of glycidamide, a 66 
metabolite of the probable human carcinogen acrylamide. The results may elucidate the 67 
cancer risks associated with exposure to acrylamide, commonly found in tobacco smoke, 68 
thermally processed foods and beverages.   69 
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Introduction 70 
Cancer can be caused by chemicals, complex mixtures, occupational exposures, physical 71 
agents, and biological agents, as well as lifestyle factors. Many human carcinogens show a 72 
number of characteristics that are shared among carcinogenic agents (1). Different human 73 
carcinogens may exhibit a spectrum of these key characteristics, and operate through 74 
separate mechanisms to generate patterns of genetic alterations. Recognizable patterns of 75 
genetic alterations or mutational signatures characterize carcinogens that are genotoxic. 76 
Recent work shows that these DNA sequence changes can be expressed in simple 77 
mathematical terms that enable mutational signatures to be extracted from thousands of 78 
cancer genome sequencing data sets (2). Several of the over 30 identified mutational 79 
signatures have been attributed to specific external exposures or endogenous factors 80 
through epidemiological and experimental studies (2). However, about 40% of the current 81 
signatures remain of unknown origin, and additional, thus far unrecognized, signatures are 82 
likely to be defined in rapidly accumulating cancer genome data. Well-controlled 83 
experimental exposure systems can thus help identify the underlying causes of known 84 
orphan mutational signatures as well as define new patterns generated by candidate 85 
carcinogens (reviewed in (3,4)). 86 
 Various diet-related exposures contribute to the human cancer burden. Examples 87 
include contaminants in food or alternative medicines, such as aflatoxin B1 (AFB1) or 88 
aristolochic acid (AA). The mutagenicity of these compounds is well-documented; AFB1 89 
induces predominantly C:G>A:T base substitutions and AA causes T:A>A:T transversions. 90 
The characteristic mutations coupled with information on the preferred sequence contexts in 91 
which they are likely to arise allowed unequivocal association of exposure to AFB1 or AA 92 
with specific subtypes of hepatobiliary or urological cancers, respectively (5-13).  93 
 Among dietary compounds with carcinogenic potential, acrylamide is of special 94 
interest due to extensive human exposure. Important sources of exposure to acrylamide 95 
include tobacco smoke (14), coffee (15), and a broad spectrum of occupational settings (16). 96 
Dietary sources of acrylamide comprise carbohydrate-rich food products that have been 97 
subject to heating at high temperatures. This is due to Maillard reactions, which involve 98 
reducing sugars and the amino acid asparagine, present in potatoes and cereals (17). There 99 
is sufficient evidence that acrylamide is carcinogenic in experimental animals (18,19) and it 100 
has been classified as a probable carcinogen (Group 2A) by the International Agency for 101 
Research on Cancer in 1994 (16). The association of dietary acrylamide exposure with 102 
renal, endometrial and ovarian cancers has been explored in recent epidemiological studies 103 
(20,21). However, accurate acrylamide exposure assessment in epidemiological studies 104 
based on questionnaires has been difficult, and more direct measures of molecular markers, 105 
such as hemoglobin adduct levels, may not yield conclusive findings on past exposures (22-106 
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27). An improved understanding of its mechanism of action using well-controlled 107 
experimental systems is critical for understanding the potential carcinogenic risk associated 108 
with exposure. 109 
 Acrylamide undergoes oxidation by cytochrome P450, producing the reactive 110 
metabolite glycidamide that is highly efficient in DNA binding due to its electrophilic epoxide 111 
structure (28-30). The Hras mutation load in neoplasms of mice exposed to acrylamide or 112 
glycidamide was found to be considerably higher in mice treated with glycidamide (31). This 113 
finding is corroborated by a considerably higher mutation frequency in the cII reporter gene 114 
of Big Blue mouse embryonic fibroblasts treated with glycidamide in comparison to 115 
acrylamide (32,33). Mutation analysis in different experimental in vivo and in vitro models 116 
using reporter genes showed an increased association of acrylamide and glycidamide 117 
exposure with T:A>C:G transitions, as well as T:A>A:T and C:G>G:C transversion mutations 118 
(31-36), whereas glycidamide exposure was also characterized by C:G>A:T transversions 119 
(33). However, these proposed acrylamide- and glycidamide-specific mutation patterns were 120 
based on limited mutation counts in reporter genes and thus do not reflect the complexity of 121 
genome-wide distributions and profiles. Based on the limited data available thus far, it is not 122 
possible to translate adequately the reported mutation types (T:A>C:G, T:A>A:T, C:G>G:C, 123 
C:G>A:T) to global alteration patterns.  124 
 The advent of massively parallel sequencing has created the opportunity to study a 125 
large number of mutations in a single sample, thus significantly enhancing the power of 126 
mutation analysis in experimental models and enabling reliable identification of specific 127 
sequence contexts for the induced alterations. Analogously to human cancer genome 128 
projects, genome-scale mutational signatures can be extracted from highly controlled 129 
carcinogen exposure experiments using mammalian cell and animal models coupled with 130 
advanced mathematical approaches (2,3,37,38). 131 
 Here we report the systematic assessment of acrylamide and glycidamide 132 
mutagenicity based on DNA adduct formation and mutation profile analysis using massively 133 
parallel sequencing in a cell model amenable to the analysis of carcinogen-induced mutation 134 
patterns and their impact on the resulting cell phenotype (3,37-39). We identify a specific 135 
and robust mutational signature attributable to glycidamide, and by computationally 136 
interrogating human cancer genome-wide mutation data, we characterize glycidamide 137 
signature-positive tumors, thereby highlighting a potential contribution of 138 
acrylamide/glycidamide exposure to carcinogenesis in humans. 139 
 140 
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Materials and methods 141 
Source and authentication of primary cells 142 
Primary Human-p53 knock-in mouse embryonic fibroblasts (Hupki MEFs) were isolated from 143 
13.5-day old Trp53tm/Holl mouse embryos from the Central Animal Laboratory of the 144 
Deutsches Krebsforschungszentrum, Heidelberg, as described previously (40). The mice 145 
had been tested for Specific Pathogen-Free (SPF) status. The derived primary cells were 146 
genotyped for the human TP53 codon 72 polymorphism (Table 1) to authenticate the 147 
embryo of origin. Cells from three different embryos (E210, E213 and E214) were used for 148 
the exposure experiments (Table 1). All subsequent cell cultures were routinely tested at all 149 
stages for the absence of mycoplasma. 150 
 151 
Cell culture, exposure and immortalization 152 
The primary MEF cells were expanded in Advanced DMEM supplemented with 15% fetal 153 
calf serum, 1% penicillin/streptomycin, 1% pyruvate, 1% glutamine, and 0.1% β-mercapto-154 
ethanol. The cells were then seeded in six-well plates and, at passage 2, exposed for 24 155 
hours to acrylamide (A4058, Sigma), glycidamide (04704, Sigma), or vehicle (PBS). 156 
Acrylamide exposure was carried out in the absence or presence of 2% human S9 fraction 157 
(Life Technologies) complemented with NADPH (Sigma). Exposed and control primary cells 158 
were cultivated until they bypassed senescence and immortalized clonal cell populations 159 
could be isolated (41). The human mammary epithelial cell (HMEC) cultures utilized in this 160 
study for whole-genome sequencing (WGS) were generated from benzo[a]pyrene (B[a]P) 161 
exposed HMEC described previously (42,43). 162 
 163 
MTT assay for cell metabolic activity and viability 164 
Cells were seeded in 96-well plates and treated as indicated. Cell viability was measured 48 165 
hours after treatment cessation using CellTiter 96® Aqueous One solution Cell Proliferation 166 
Assay (Promega). Plates were incubated for 4 hours at 37°C and absorbance was 167 
measured at 492 nm using the APOLLO 11 LB913 plate reader. The MTT assay was 168 
performed in triplicates for each experimental condition. 169 
 170 
γH2Ax Immunofluorescence 171 
Immunofluorescence staining was carried out using an antibody specific for Ser139-172 
phosphorylated H2Ax (γH2Ax) (9718, Cell Signaling Technology). Primary MEFs were 173 
seeded on coverslips in 12 well-plates. The cells were incubated in with γH2Ax-antibody 174 
(1:500 in 1% BSA) at 4°C overnight. Subsequent incubation with a fluorochrome-conjugated 175 
secondary antibody (4412, Cell Signaling Technology) was carried out for 60 minutes at 176 
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room temperature. Coverslips were mounted in Vectashield mounting medium with DAPI 177 
(Eurobio). Immunofluorescence images were captured using a Nikon Eclipse Ti. 178 
 179 
DNA adduct analysis 180 
Glycidamide-DNA adducts (N7-(2-carbamoy-2-hydroxyethyl)-guanine (N7-GA-Gua) and N3-181 
(2-carbamoy-2-hydroxyethyl)-adenine (N3-GA-Ade)) were quantified by liquid 182 
chromatography-mass spectrometry (LC-MS/MS) with stable isotope dilution as previously 183 
described (44) (see Supplementary Materials and Methods for details). The LC-MS/MS used 184 
for quantification consisted of an Acquity UPLC system (Waters) and a Xevo TQ-S triple 185 
quadrupole mass spectrometer (Waters). The same MRM transitions as previously 186 
described (44) were monitored with a cone voltage of 50V and collision energy of 20eV for 187 
each adduct transition and its corresponding labeled isotope transition. 188 
 189 
TP53 genotyping 190 
Exons 4 to 8 of the knocked-in human TP53 gene (NC_000017.11) were sequenced using 191 
standard protocols. Sanger sequencing of PCR products was performed at Biofidal (Lyon, 192 
France). TP53 primer sequences are listed in Supplementary Materials and Methods. 193 
Resulting sequences were analyzed using the CodonCode Aligner software. 194 
 195 
Library preparation and whole-exome sequencing (WES)  196 
Library preparation was carried out using the Kapa Hyper Plus library preparation kit (Kapa 197 
Biosystems) according the manufacturer’s instructions. Exome capture was performed using 198 
the SureSelect XT Mouse All Exon Kit (Agilent Technologies). Eighteen exome-captured 199 
libraries were sequenced in the paired-end 150 base-pair run mode using the Illumina 200 
HiSeq4000 sequencer.  201 
 202 
Processing of WES data  203 
Fastq files were analyzed for data amount and quality using FastQC (0.11.3) and were 204 
processed with an in-house pipeline for adapter trimming and alignment to the mm10 205 
genome (release GRCm38). These components of the pipeline are publicly available at 206 
https://github.com/IARCbioinfo/alignment-nf. The resulting alignment files had a mean depth-207 
of-coverage of 135 and 175 for acrylamide and glycidamide samples, respectively. All 208 
alignment files can be accessed from the NCBI Sequence Read Archive (SRA) data portal 209 
under the BioProject accession number PRJNA238303. Two somatic variant callers were 210 
employed with default parameters in order to detect single base substitutions (SBS) and 211 
small insertions/deletions (indels) (MuTect 1.1.6-4 and Strelka 1.015) in exposed clones, 212 
using primary cells as normal samples. Each immortalized clone was compared to primary 213 
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MEFs from three different embryos (conditions Prim_1, Prim_2, and Prim_3). The overlap of 214 
the variant calling outcome with respect to the different primary MEFs showed concordance 215 
close to 80% (Suppl. Fig. S1) with MuTect exhibiting more stringent calling performance. 216 
Thus, mutation data obtained from the MuTect variant caller were further processed with the 217 
MutSpec suite ((45); https://github.com/IARCbioinfo/mutspec). For more details, see 218 
Supplementary Materials and Methods and the summary of sequencing metrics (Suppl. 219 
Table S1), the list of identified MuTect SBS variants (Suppl. Table S2) and indels (Suppl. 220 
Table S3).  221 
 222 
Bioinformatics and statistical analyses  223 
The FactoMiner R package (R package version 3.3.2; https://cran.r-224 
project.org/web/packages/FactoMineR) was used to perform the principal component 225 
analysis (PCA). To perform the transcription strand bias (SB) analyses, p-values were 226 
calculated using Pearson’s χ2 test. As multiple comparisons were assessed, the p-value 227 
was adjusted by applying a false discovery rate (FDR). Statistical analyses were carried out 228 
using the stats R package. The SB was considered statistically significant at p-value ≤ 0.05. 229 
To analyze samples mutation spectra and treatment-specific mutational signatures, filtered 230 
mutations were classified into 96 types corresponding to the six possible base substitutions 231 
(C:G>A:T, C:G>G:C, C:G>T:A, T:A>A:T, T:A>C:G, T:A>G:C) and the 16 combinations of 232 
flanking nucleotides immediately 5’ and 3’ of the mutated base. Mutation patterns were then 233 
deconvoluted into mutational signatures using the non-negative matrix factorization (NMF) 234 
algorithm (46,47). The reconstruction error calculation evaluated the accuracy with which the 235 
deciphered mutational signatures describe the original mutation spectra of each sample by 236 
applying Pearson correlation and cosine similarity.  237 
 In order to clean up the profile of the glycidamide mutational signature from the 238 
residual signature 17 signal and to increase the stability of NMF decomposition, we supplied 239 
the NMF input by adding samples with a high level of signature 17 (over 65% contribution as 240 
determined by independent NMF analysis, see Supplementary Materials and Methods).  241 
 Cosine similarity analysis was used to evaluate the concordance of the newly 242 
identified T:A>A:T-rich mutational signature of glycidamide with the previously reported 243 
mutational signatures characterized by a predominant T:A>A:T content. These comprised 244 
COSMIC signatures 22 (AA), 25 and 27 (both of unknown etiology(2)), the experimentally 245 
derived mutational signature of AA (37,45), 7,12-dimethylbenz[a]anthracene (DMBA) 246 
(48,49), and urethane (50). 247 
 We employed the mutational signature activity (mSigAct) software’s sparse signature 248 
assignment function (sparse.assign.activity) (13) to assess the presence of the experimental 249 
mutational signatures of glycidamide and benzo[a]pyrene in whole-genome somatic mutation 250 
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data from 38 lung adenocarcinomas, 48 lung squamous carcinomas, and 320 liver cancers 251 
from the ICGC Pan-Cancer Analysis of Whole Genomes (PCAWG) study. We excluded 244 252 
hyper-mutated microsatellite unstable and aristolochic acid signature-containing liver tumors 253 
as the presence of high numbers of T>A mutations adversely prevented assessment of the 254 
possible presence of the glycidamide signature. A set of 11 active COSMIC mutational 255 
signatures were identified in the remaining tumor samples (excluding COSMIC signature 4). 256 
We defined a ‘pure’ experimental C>N benzo[a]pyrene signature by WGS (using 257 
Illumina HiSeq4000 by Genewiz, NJ, USA) of finite lifespan post-stasis clones derived from 258 
primary human mammary epithelial cells (HMEC) treated with B[a]P as previously described 259 
(42,43,51). The read alignment to NCBI GRCh38 genome build, variant calling, filtering and 260 
annotation were consistent with the MutSpec pipeline described above (45). Proportion 261 
matrices of the experimental GA-signature, the GA-signature normalized to the human 262 
genome trinucleotide frequency to allow for human PCAWG data screening, and the whole-263 
genome B[a]P signature are available in Suppl. Table S4. 264 
Results 265 
Acrylamide and glycidamide induce cytotoxic and genotoxic responses in Hupki 266 
MEFs 267 
Upon exposure of primary Hupki MEFs to a range of concentrations of acrylamide (ACR) (in 268 
the absence or presence of the S9 fraction) and its metabolite, glycidamide (GA), we 269 
observed a dose-dependent cytotoxic effect on the cells for either compound (Fig. 1A). This 270 
analysis informed the selection of two conditions for the ACR exposure to be used in the 271 
subsequent exposure/immortalization experiments, 10 mM ACR for 24 hours in the absence 272 
of human S9 fraction, and 5 mM ACR for 24 hours in the presence of S9 fraction, which 273 
elicited 50% (range 30-70%) decrease in cell viability. The IC50 condition for GA was used 274 
for subsequent mutagenesis analysis, corresponding to a 24-hour treatment with 3 mM of 275 
the compound. The genotoxic effects of either ACR or GA manifested by a marked increase 276 
in γH2Ax staining in the exposed cell populations, in comparison to the mock-treated control 277 
cells (Fig. 1B). 278 
 279 
Immortalized MEF cells accumulate TP53 mutations following acrylamide or 280 
glycidamide treatment  281 
Primary MEF cultures from three different embryos (Prim_1, Prim_2, and Prim_3) were 282 
exposed to ACR or GA using the established conditions and multiple immortalized clones 283 
were derived. MEF senescence and immortalization phases were evident from the growth 284 
curves generated for each culture (Suppl. Fig. S2). Subsequently, the clones derived from 285 
ACR exposure (ACR clones) and GA exposure (GA clones) and spontaneous 286 
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immortalization (Spont), were pre-screened for TP53 mutations by Sanger sequencing, to 287 
assess the mutagenic process prior to exome-scale analysis. In the context of ACR 288 
treatment, clones obtained from the Prim_2 MEFs that were heterozygous for the 289 
polymorphic site in codon 72 showed a loss of heterozygosity involving a loss of the proline 290 
allele in the ACR_1 clone whereas the arginine allele was lost in ACR_2, giving rise to a 291 
hemizygous clone (Table 1). No TP53 mutations were observed in any of the three Spont 292 
clones, whereas 3 out of 7 ACR clones and 1 of 5 GA clones carried non-synonymous TP53 293 
mutations (Table 1). The detected mutations indicated specific selection for mutations in the 294 
TP53 gene during cell immortalization and confirmed the clonal nature of MEF 295 
immortalization. 296 
 297 
Analysis of mutation spectra 298 
Whole-exome sequencing of all spontaneously immortalized and exposed clones and 299 
subsequent extraction of acquired variants revealed that the total number of acquired SBS 300 
did not differ markedly between the ACR and Spont clones. The Spont clones harbored on 301 
average 190 (median = 151, range = 141-277) SBS, whereas the ACR clones had on 302 
average 208 (median = 173, range = 151-262) SBS. In contrast, the total number of SBS 303 
was considerably increased in the GA clones, with an average of 485 SBS (median = 448, 304 
range = 370-592) (Suppl. Table S1 and S2). This finding suggests markedly stronger 305 
mutagenic properties of GA in the MEFs. To estimate the extent of sequencing-related 306 
damage in our samples, we determined the GIV score of each sample as described in 307 
Materials and Methods and in (52). No detectable damage for any of the mutation types was 308 
observed in our dataset (data not shown). The ACR exposed samples exhibited an overall 309 
diffuse pattern across the six different SBS types (Suppl. Fig. S3). The Spont clones showed 310 
an enrichment of C:G>G:C SBS in the 5’-GCC-3’ context, which was also present at varying 311 
levels in the exposed cultures. This particular mutation type appears to be related to the 312 
culture conditions used for the immortalization assay, as its presence has previously been 313 
noted upon spontaneous as well as exposure-driven MEF immortalization (37). No 314 
significant transcription strand bias was observed for any of the mutation classes in the 315 
Spont or ACR clones (Suppl. Fig. S4). In the five clones derived from the GA-treated primary 316 
MEF cultures, we observed an enrichment of acquired T:A>A:T and C:G>A:T transversions 317 
and T:A>C:G transitions (Suppl. Fig. S3B), marked by significant transcription strand bias 318 
(Suppl. Fig. S4).  319 
 PCA performed on the resulting 6-class SBS spectra unambiguously separated the 320 
GA clones from the remaining experimental conditions (Fig. 2A). The analysis of indels 321 
(listed in Suppl. Table S3) showed lower numbers of these alterations in the GA-associated 322 
clones compared to the ACR or Spont clones (Fig. 2B). This suggests that a higher 323 
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accumulation of SBS may selectively promote the senescence bypass and selection of the 324 
GA clones, with a decreased functional contribution of indels, while an inverse scenario is 325 
plausible in case of the Spont and ACR clones, reminiscent of a previous report based on 326 
the Big Blue mouse embryonic fibroblasts and cII transgene (53).  327 
 328 
Variant allele frequency analysis 329 
Variant allele frequency (VAF) analysis was carried out for GA clones. Overall, a significant 330 
proportion of acquired mutations was present at allelic frequencies between 25-75% (Suppl. 331 
Fig. S5). Upon grouping of substitutions into bins of high (67-100%), medium (34-66%) and 332 
low (0-33%) VAF, the predominant GA-specific mutation types (T:A>A:T, T:A>C:G and 333 
C:G>A:T) started manifesting at high VAF, whereas the 5’-NTT-3’ alterations, corresponding 334 
to the COSMIC signature 17 previously reported to arise in cultured mouse cells including 335 
MEFs (38,54,55) showed lower VAF, therefore a later appearance in the cultures (Suppl. 336 
Fig. S6). This observation suggests the early effects of the GA exposure and the 337 
reproducible contribution of the induced mutations to the senescence bypass and their clonal 338 
propagation during the immortalization stage. 339 
 340 
Mutational signature analysis 341 
Using NMF, we extracted the mutational signatures from all the MEF clones. Using 342 
computed statistics for estimating the number of signatures, three signatures were identified 343 
as an optimal number, with signatures A and C enriched in the Spont and ACR clones, and 344 
signature B selectively enriched in the GA clones (Fig. 2C,D). Reconstruction of the 345 
observed mutation spectra supports the robustness of the signature analysis with strong 346 
Pearson’s correlation and cosine similarity in GA-derived clones (Fig. 2D). In signature C 347 
and also to a lesser extent in signatures A and B, we observed an admixture of a pattern 348 
identical to the orphan COSMIC signature 17 (T:A>G:C in a 5’-NTT-3’ trinucleotide context), 349 
described in various human cancers (most notably esophageal adenocarcinoma), but also 350 
seen in aflatoxin B1-driven mouse liver cancers (11), as well as primary MEF-derived clones 351 
(37,38). In in vitro contexts, this signature has been linked to cell culture conditions and 352 
associated oxidative stress (54,55). To refine further the obtained experimental signatures, 353 
we developed a signature ‘baiting’ approach that combined the MEF clones data with 354 
signature 17-rich data from esophageal adenocarcinomas from the ICGC ESAD-UK study 355 
for new NMF analysis (56). This resulted in considerable reduction (average = 47%, median 356 
= 48%) of the signature 17-specific most prominent T>G peaks and a more refined pattern 357 
for signature B, associated primarily with GA treatment (Fig. 3A and Suppl. Fig. S7). This 358 
putative GA signature retains the predominant enrichment for the T:A>A:T transversions and 359 
T:A>C:G transitions in the 5’-CTG-3’ and 5’-CTT-3’ trinucleotide contexts, and the C:G>A:T 360 
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component. Moreover, these mutation types were marked by significant transcription strand 361 
bias (Fig. 3B and Suppl. Fig. S4), exhibiting higher accumulation of mutations on the non-362 
transcribed strand consistent with the decreased efficiency of the transcription-coupled 363 
nucleotide excision repair due to adduct formation. 364 
 365 
DNA adduct analysis 366 
Following metabolic activation, acrylamide induces well-characterized glycidamide DNA 367 
adducts at the N7- and N3-positions of guanine and adenine, respectively. LC-MS/MS-based 368 
adduct quantification revealed the absence of these adducts in the spontaneously 369 
immortalized control samples as well as in MEFs exposed to acrylamide in the absence of 370 
S9 fraction (levels below the limit of detection). This suggests the lack of CYP2E1 activity, 371 
which is required for the metabolism of acrylamide to glycidamide, in the MEFs. Upon 372 
addition of human S9 fraction, N7-GA-Gua levels increased to 11adducts/108 nucleotides, 373 
suggesting limited metabolic activation of acrylamide due to the presence of enzymatic 374 
activity in the S9 fraction (Fig. 3C and Suppl. Fig. S8). Glycidamide-exposed cells exhibited 375 
significantly increased DNA adduct levels, with both N7-GA-Gua and N3-GA-Ade observed 376 
at very high average levels, 49 000 adducts/108 nucleotides and 350 adducts/108 377 
nucleotides, respectively, after subtracting the trace amount of contamination from the 378 
internal standard (Fig. 3C and Suppl. Fig. S8). 379 
 380 
Comparison of the glycidamide signature to known signatures characterized by 381 
prominent T:A>A:T profiles  382 
We next performed cosine similarity analysis of the putative GA signature and all known 383 
T:A>A:T-rich signatures extracted from primary cancers as well as experimental systems 384 
(Fig. 3D and Suppl. Fig. S9). The best match was 84% pattern similarity with COSMIC 385 
signature 25 (derived from four Hodgkin lymphoma cell lines) (Fig. 3D). However, unlike the 386 
GA signature, COSMIC signature 25 exhibits strand bias for only T:A>A:T mutations and no 387 
transcription strand bias for the T:A>C:G mutations. Thus, the mutation patterns and strand 388 
bias on all three main mutation types generated by GA treatment (Fig. 3A,B) appear specific 389 
and novel. 390 
 391 
Glycidamide signature screening in human tumor data from the ICGC PCAWG 392 
The initial mSigAct test performed on PCAWG data from lung and liver tumors indicated a 393 
marked presence of the GA signature. This observation was in keeping with the presence of 394 
acrylamide in tobacco smoke and was further corroborated by a cosine similarity of 94% 395 
between the adenine (T>N) components of COSMIC signature 4 (tobacco smoking) and the 396 
GA signature (Fig. 4A). We thus hypothesized that COSMIC signature 4 reflects co-397 
Page 12 of 62Carcinogenesis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
12 
 
exposure to B[a]P (generating C>N/guanine mutations with transcription strand bias) and to 398 
GA (generating T>N/adenine mutations with transcription strand bias) (Fig. 4A,B). To 399 
provide further experimental evidence, we generated a ‘pure’ B[a]P mutational signature by 400 
whole-genome sequencing of cell clones derived from B[a]P-exposed normal human 401 
mammary epithelial cells (HMEC). This yielded a robust signature characterized by 402 
predominant strand biased guanine (mainly C>A) mutation levels and negligibly mutated 403 
adenines (T>N) (Fig. 4A,B). Next, we used mSigAct to interrogate the PCAWG tumor 404 
samples for the level of exposure to the experimentally defined GA and B[a]P signatures 405 
(alongside other COSMIC mutational signatures) in 48 lung squamous carcinomas, 38 lung 406 
adenocarcinomas, and 320 liver cancers. We compared these to estimated levels of 407 
exposure to COSMIC signature 4, and found that in the lung cancers, a combination of the 408 
GA and B[a]P signatures accounted for very similar numbers of mutations as COSMIC 409 
signature 4, thus further supporting the hypothesis that COSMIC signature 4 represents 410 
combined and highly correlated exposure to GA and B[a]P (Fig. 4C). Compared to lung 411 
cancers, we found more variability in the assignment of mutation numbers to GA and B[a]P 412 
versus COSMIC signature 4 in liver cancers (Fig. 4C), which may reflect a decreased 413 
relationship between GA and B[a]P exposure due to generally more complex exposure 414 
history in the liver. The successful reconstruction of COSMIC signature 4 by the 415 
experimental GA- and B[a]P- signatures in the lung and liver human tumors enabled correct 416 
assignment of the GA-signature in a subset of 29 lung adenocarcinomas, 46 lung SCC and 417 
26 liver tumors (Fig. 4D). The SBS counts corresponding to GA-mutational signature ranged 418 
between 300 up to 43,000 mutations/per sample in lung tumors, and between 190 to 23,000 419 
mutations/per sample in liver tumors (Fig. 4D and Suppl. Table S5). These findings indicate 420 
exposure to glycidamide linked to tobacco smoking – when concomitant with B[a]P-421 
signature, or through diet or occupation – in the absence of B[a]P signature (samples Liver-422 
HCC::SP112224; Liver-HCC::SP49551; Liver-HCC::SP50105; Liver-HCC::SP98861; Liver-423 
HCC::SP50183, see Suppl. Fig. S10 and Suppl. Table S5). 424 
Discussion 425 
In this study we report the identification of an exome-wide mutational signature for 426 
glycidamide, a metabolite of the probable human carcinogen acrylamide. The newly 427 
identified signature is based on massively parallel sequencing performed in a well-controlled 428 
experimental carcinogen exposure-clonal immortalization model, revealing characteristic 429 
mutagenic effects of glycidamide. The glycidamide mutational signature presented here and 430 
the results of statistical assessment of its presence in multiple human tumor types may help 431 
clarify the thus-far tenuous association of acrylamide with human cancer.  432 
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 In concordance with its in vivo carcinogenicity in rodents (16,19,31,57), our findings 433 
in the established MEF carcinogen exposure and immortalization system suggest that 434 
characteristic mutagenic effects may play a role during acrylamide/glycidamide-driven tumor 435 
development. In contrast to glycidamide, acrylamide exposure led neither to an increased 436 
number of SBS nor did it induce characteristic mutation types in the MEF exposure system. 437 
Despite the absence of a mutagenic effect of acrylamide in our experiments, acrylamide and 438 
glycidamide exposures induce an almost identical set of tumors in both mice and rats, 439 
providing a substantial argument for a glycidamide-mediated tumorigenic effect of 440 
acrylamide (19). This is further supported by mechanistic studies showing that lung tissue 441 
from mice exposed to acrylamide and glycidamide displays comparable DNA adduct 442 
patterns as well as similar mutation frequencies in the cII transgene (36). Similar 443 
observations had been made in the context of in vitro mutagenicity of acrylamide in human 444 
and mouse cells, suggesting the key role for epoxide metabolite glycidamide to form pre-445 
mutagenic DNA adducts (33). 446 
 As shown by our adduct analysis, acrylamide is not efficiently metabolized by MEFs. 447 
This finding is in keeping with the results from previous animal carcinogenicity studies. In 448 
fact, glycidamide induces hepatocellular carcinomas in neonatal B6C3F1 mice, whereas 449 
administration of acrylamide does not increase the tumor incidence. This has been attributed 450 
to the inability of neonatal mice to efficiently metabolize acrylamide (31). Moreover, in 451 
contrast to acrylamide treatment, glycidamide induces tumors of the small intestine in a 452 
dose-dependent manner upon perinatal exposure (57) and similar observations were made 453 
for glycidamide mutagenicity in vitro (33). We compensated for the lack of proper acrylamide 454 
metabolic activation by the addition of human S9 fraction, and the assessment of DNA 455 
adducts indeed suggests acrylamide metabolic activation upon addition of S9. However, the 456 
adduct levels are substantially lower compared to glycidamide exposure, which may account 457 
for the observed differences in mutagenicity. Interestingly, a consistent minor contribution of 458 
the glycidamide mutational signature was detected in the majority of ACR clones, whereas it 459 
was absent in the Spont clones. This raises the possibility that partial metabolic activation of 460 
acrylamide in the MEF system resulted in low levels of glycidamide. However, a clear 461 
mutational signature in the employed experimental setting was achieved only by exposing 462 
the cells directly to glycidamide. 463 
Single reporter gene studies had previously linked acrylamide and glycidamide 464 
exposure to multiple different mutation types. Thanks to the larger number of mutations 465 
captured by exome sequencing, we were able to attribute to the glycidamide exposure a 466 
particular mutational signature characterized by strand-biased C:G>A:T and T:A>A:T 467 
transversions, and T:A>C:A transitions towards the non-transcribed strand suggesting a 468 
formation of DNA-adducts. The presence of N7-GA-Gua and N3-GA-Ade, two well-469 
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characterized glycidamide DNA adducts originating from the metabolic conversion of 470 
acrylamide (30,44,53), shows a remarkable relationship between DNA adduct profiles and 471 
the putative mutational signature of glycidamide. N3-GA-Ade and N7-GA-Gua are 472 
depurinating adducts. They can result in apurinic/apyrimidinic sites, which, during replication, 473 
induce the mis-incorporation of deoxyadenine, leading to the observed T:A>A:T and 474 
C:G>A:T transversions of the glycidamide signature, respectively. The third mutation type 475 
specifically enriched in the glycidamide signature, T:A>C:G transitions, has been ascribed to 476 
the N1-GA-Ade adduct, a miscoding adduct and the most commonly identified adenine 477 
adduct in vitro (35,44,53,58). Levels of the guanine adduct were especially high in the 478 
exposed MEF cells, whereas the associated C:G>A:T transversions in the resulting post-479 
senescence clones were less represented. This could reflect differences in DNA repair 480 
efficiency concerning individual GA-DNA adduct species, or the fact that the resulting clones 481 
are derived from single cells whereas the GA-DNA adducts were measured on average in 482 
the bulk primary cell population. A mechanism of negative selection of cells with high N7-483 
GA-Gua adduct burden is also plausible.  484 
We observed consistent presence of COSMIC signature 17 in the data generated 485 
from the untreated and treated MEF clones. The etiology of signature 17 remains unknown. 486 
While some candidate causal factors have been proposed in esophageal adenocarcinoma 487 
and gastric cancers (e.g., inflammatory conditions due to acid reflux, H. pylori) (56) and in 488 
cultured mouse cell systems (54,55), further studies are required to establish why signature 489 
17 tends to arise in vitro in immortalized clones derived from mouse embryonic fibroblasts as 490 
observed in our study and also previous work (38).  491 
 Genome-scale sequencing of tumor tissues will be needed to verify, in vivo, the 492 
glycidamide mutational signature identified in this study. The established animal models 493 
(18,19) of acrylamide- and glycidamide-mediated tumorigenesis provide a suitable starting 494 
point, and it would be interesting to compare mutational signatures derived from these 495 
models with the in vitro results. The identified glycidamide signature with its extended 496 
features of transcription strand bias for the major mutation types differs from the currently 497 
known COSMIC signatures (Fig. 3D). In addition, we show that in the cancer genome 498 
sequencing data sets from the ICGC PCAWG effort, the putative glycidamide-mutational 499 
signature can be identified in a subset of tumors of the lung and liver (sites of possible 500 
acrylamide exposure due to tobacco smoking), based on combining experimentally derived 501 
signatures with sophisticated computational signature reconstruction approaches (Fig. 4). 502 
 The continued interest in understanding the contribution of acrylamide and its 503 
electrophilic metabolite glycidamide to cancer development reflects recent accumulation of 504 
new mechanistic data on the animal carcinogenicity of the compounds. The possible 505 
carcinogenic effects in humans have been recommended for re-evaluation by the Advisory 506 
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Group to the Monographs Program of the International Agency for Research on Cancer (59). 507 
Our findings related to the reconstruction of COSMIC signature 4 using the experimental 508 
GA-signature and B[a]P signature, together with the presence of the GA signature in the 509 
lung and liver cancer data are relevant given the established high contents of acrylamide in 510 
tobacco smoke. Despite the absence of prominent T>N (adenine) mutations in the 511 
experimental B[a]P exposure setting, we cannot exclude a possibility that in the human lung 512 
cells the adenine residues can be additionally targeted by other tobacco carcinogens such 513 
as benzo[a]pyrene derivatives or nitrosamines. Importantly, five liver tumor samples 514 
identified in this study harbored the GA signature but the major features of signature 4 as 515 
represented by the experimental B[a]P signature were absent (Suppl. Fig. S10, Suppl. Table 516 
S5). These tumors are thus of particular interest as they could reflect dietary or occupational 517 
exposure to acrylamide.  518 
 The presented mutational signature of glycidamide and its potential use for screening 519 
of cancer genome sequencing data may provide a basis for relevant assessment of cancer 520 
risk through new carefully designed molecular cancer epidemiology studies. Future 521 
validation analyses involving e.g. GA-DNA adduct monitoring in non-tumor tissue of cancer 522 
patients or in animal exposure models are warranted to provide additional evidence that the 523 
predominant T>N mutations in the cancers identified in this study indeed originate from 524 
exposure to acrylamide and its reactive metabolite glycidamide. 525 
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Figure legends 691 
Figure 1: Acrylamide- and glycidamide-induced cytotoxicity and genotoxicity in vitro. (A) Cell 692 
viability, following 24-hour treatment of primary MEFs with the indicated concentrations of 693 
acrylamide (top panel), in the absence (diamonds) and presence (circles) of human S9 694 
fraction, and glycidamide (bottom panel), as determined by MTT assay. Absorbance was 695 
measured 48 hours after treatment cessation and was normalized to untreated cells. The 696 
results are expressed as mean percent ±SD of three replicates. (B) DNA damage 697 
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assessment by immunofluorescence with an antibody specific for Ser139-phosphorylated 698 
histone H2Ax (ɣH2Ax). Primary MEFs were treated with acrylamide or glycidamide for 24 699 
hours prior to immunofluorescence. Compound concentrations used were based on 20-70% 700 
viability reduction in the MTT assay: 10 mM acrylamide, 5 mM acrylamide in the presence of 701 
S9 fraction and 3 mM glycidamide. ACR: acrylamide; GA: glycidamide.  702 
Figure 2: Analysis of the mutation patterns derived from exome sequencing data from 703 
immortalized Hupki MEF clones. (A) Principle component analysis (PCA) of WES data. PCA 704 
was computed using as input the mutation count matrix of the clones that immortalized 705 
spontaneously (Spont) or were derived from exposure to acrylamide (ACR) or glycidamide 706 
(GA). Each sample is plotted considering the value of the first and second principal 707 
components (Dim1 and Dim2). The percentage of variance explained by each component is 708 
indicated within brackets on each axis. Spont, ACR- and GA-exposed samples are 709 
represented by differently colored symbols. (B) Representation of small insertions and 710 
deletions (indels) counts within the immortalized clones as determined by the Strelka variant 711 
caller. (C) Mutational signatures identified by non-negative matrix factorization (NMF) in the 712 
15 Hupki MEF-derived clones (sig A, sig B, and sig C). X-axis represents the trinucleotide 713 
sequence context. Y-axis represents the frequency distribution of the mutations. The 714 
predominant trinucleotide context for T:A > A:T mutations is indicated in sig B (5’-CTG-3’). 715 
The trinucleotide contexts for C:G > G:C (5’-GCC-3’) and T:A > G:C mutations (5’-NTT-3’) 716 
are highlighted in sig C. (D) Contribution of the identified signatures to each sample (X-axis), 717 
assigned either by absolute SBS counts or by proportion (bar graphs). The reconstruction 718 
accuracy of the identified mutational signatures in individual samples is shown in the bottom 719 
scatter plot (Y-axis value of 1 = 100% accuracy). 720 
Figure 3: (A) Refinement of GA signature. The contribution of signature 17 (T:A>G:C in 5’-721 
NTT-3’ context), present in all clones, was decreased by performing NMF on Hupki samples 722 
pooled with primary tumor samples with high levels of signature 17 (see Methods). (B) 723 
Transcription strand bias analysis for the six mutation types in GA-exposed clones. For each 724 
mutation type, the number of mutations occurring on the transcribed (T) and non-transcribed 725 
(N) strand is shown on the Y-axis. *** p < 10-8 ; * p < 10-2. (C) DNA adducts analysis as 726 
determined by LC-MS/MS. Levels of N7-GA-Gua adduct in ACR+S9 and GA treated MEFs 727 
and N3-GA-Ade DNA adduct level in GA treated MEFs. The data are presented as the 728 
number of adducts in 108 nucleotides. n ≥ 2. (D) Cosine similarity matrix comparing the 729 
putative glycidamide mutational signature with other A>T rich mutational signatures from 730 
COSMIC (signatures 22, 25, and 27) and from experimental exposure assays using specific 731 
carcinogens (7,12-dimethylbenz[a]anthracene (DMBA), urethane, and aristolochic acid 732 
(AA)).  733 
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Figure 4: GA signature in human primary cancer genome PCAWG data. (A) Comparison of 734 
COSMIC signature 4 with two experimentally derived signatures (B[a]P_Exp = signature in 735 
clones from benzo[a]pyrene treated HMEC cells; GA_Exp = signature in clones from 736 
glycidamide-treated MEF cells). Cosine similarity between the T>N (adenine) components of 737 
signature 4 and GA signature is shown to the right. (B) Transcription strand bias analysis for 738 
the six mutation types underlying the signatures in panel A). For each mutation type, the 739 
number of mutations occurring on the transcribed (T) and non-transcribed (N) strand is 740 
shown on the left Y-axis. The significance is expressed as –log10(p-value) indicated on the 741 
right Y-axis. *** p < 10-8 ; ** p < 10-4 ; * p < 10-2 . (C) Scatter plots show reconstruction of 742 
COSMIC signature 4 using B[a]P- and glycidamide- experimental mutational signatures in 743 
lung adenocarcinoma, lung squamous cell carcinoma and hepatocellular carcinoma from the 744 
PCAWG data set. (D) mSigAct analysis identifies the assignment and the contributions of 745 
mutational signatures (including the experimental signature_GA_Exp (red) and 746 
signature_B[a]P_Exp (blue)) to the mutation burden of a total of 101 PCAWG lung and liver 747 
tumors identified as positive for the GA signature signal. 748 
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Table 1: Summary of cell lines, treatment conditions and TP531 mutation status. 
 
Sample ID Embryo Exposure  
Conc. 
(mM) 
Exposure 
duration  
(hrs) 
coding DNA change
2
 genomic DNA change
3
 aa change 
Codon 72 
(rs1042522)
4
 
Prim_1 E210 - - - Pro/Pro 
Prim_2 E213 - - -   Arg/Pro 
Prim_3 E214 - - - Pro/Pro 
Spont_1 E213 - - - Arg/Pro 
Spont_2 E214 - - -   Pro/Pro 
Spont_3 E214 - - - Pro/Pro 
ACR_S9_1 E213 ACR 5 24 Arg/Pro 
ACR_S9_2 E213 ACR 5 24 Arg/Pro 
ACR_1 E213 ACR 10 24 c.881delA g.7577057delT p.E294fs Arg/- 
ACR_2 E213 ACR 10 24 c.818G>T g.7577120C>A p.R273L Pro/- 
ACR_3 E214 ACR 10 24 c.740A>T; c.839G>C g.7577541T>A; g.7577099C>G p.N247I; p.R280T Pro/Pro 
ACR_4 E214 ACR 10 24 Pro/Pro 
ACR_5 E214 ACR 10 24 Pro/Pro 
GA_1 E210 GA 3 24 Pro/Pro 
GA_2 E210 GA 3 24 Pro/Pro 
GA_3 E210 GA 3 24 c.309-310CC>TA g.7579377-7579378GG>TA [p.Y103Y; p.Q104K] Pro/Pro 
GA_4 E214 GA 3 24 Pro/Pro 
GA_5 E214 GA 3 24       Pro/Pro 
 
1 human TP53 gene; 2 NM_000546.4 coding sequence; 3 hg19 genomic coordinates; 4 human polymorphic site (rs1042522) 
 
 
Prim = Primary cells; Spont = spontaneously immortalized clones; ACR = acrylamide-exposure derived clones; GA = glycidamide-exposure derived 
clones. Each exposure condition was carried out in two biological replicates (embryos). S9 = human S9 fraction; Pro = proline; Arg = arginine; Arg/- 
or Pro/- = loss of allele; fs = frameshift; aa = amino acid. 
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Supplementary Figure Legends 
 
Supplementary Fig. S1: Comparison of different normalization and single-nucleotide variant 
calling strategies. Variant calling with respect to primary cell normalization. Venn diagrams show 
the overlap of variants called in glycidamide (GA)-derived clones after normalization to three 
different batches of primary cells (Prim_1, Prim_2, and Prim_3).  
Supplementary Fig. S2: Growth curves of Hupki MEFs. Primary cells were either left untreated 
(Spont) or were exposed to acrylamide (ACR±S9) or glycidamide (GA). X-axis represents days 
in culture. Y-axis represents the cumulative doubling populations. The dashed vertical line 
represents the threshold of p-value < 0.05. Arrow: compound exposure; S*: senescence; SBI: 
senescence bypass/immortalization. 
Supplementary Fig. S3: Mutation spectra derived from exome sequencing data from 
immortalized Hupki MEF clones derived from exposure to (A) acrylamide (ACR) or (B) 
glycidamide (GA), or (C) by spontaneous immortalization (Spont). X-axis represents the 
trinucleotide sequence context. Y-axis represents the frequency distribution of the mutations in 
each context. 
Supplementary Fig. S4: Illustration of the transcription strand bias derived from the analysis of 
exome sequencing data from immortalized Hupki MEF cell lines. GA: glycidamide-derived 
clones; ACR: acrylamide-derived clones; Spont: spontaneously immortalized clones. The six 
mutation types are represented by different colors. For each mutation type, the number of 
mutations occurring on the transcribed (T) and non-transcribed (N) strand, as well as the p-
values for strand bias is shown on the y-axes. The dashed grey line in each graph indicates the 
p-values for strand bias for each mutation type. The horizontal, dashed black line represents a 
significance threshold of p < 0.05.  
Supplementary Fig. S5:  Distribution of mutations based on their allelic frequencies in the five 
glycidamide (GA)-derived clones (left). Mutations in individual cell lines were ranked and plotted 
based on decreasing allelic frequency. Percentage of mutations with allelic frequency between 
25% and 75% is indicated. Percentages of the six mutation types, color-coded, among all 
mutations identified in GA clones (right). The overall mutation number for each sample is 
indicated in the centre of the pie chart. 
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Supplementary Fig. S6: Mutation type and mutation spectra analysis with respect to variant 
allele frequency (VAF). The analysis was carried out using exome sequencing data from 
immortalized Hupki MEF clones derived from exposure to glycidamide. Top left: Mutation counts 
were stratified into three VAF bins ([0-33% = low VAF]; [34-66% = medium VAF]; [67-100% = 
high VAF]). Top right: The relative contribution of the six mutation types to the overall number of 
mutations in each VAF bin is shown on the y-axis. Bottom panel: Mutation spectra (left) and 
strand bias (right) analysis for the different VAF bins. Mutation spectra analysis: X-axis 
represents the trinucleotide sequence context. Y-axis represents the frequency distribution of 
the mutations. The counts for each mutation type are indicated in parentheses. Strand bias 
analysis: For each mutation type, the number of mutations occurring on the transcribed and 
non-transcribed strand is shown on the y-axis. T: transcribed strand; N: non-transcribed strand. 
Supplementary Fig. S7: The ‘baiting’ clean-up of background signature 17 and the 
quantification of its efficiency. COSMIC signature 17 (top track) marked by the arrows observed 
in GA mutation spectra as well as in GA-mutational signature before and after baiting (clean). 
The heat-map table on the right indicates the final proportionate reduction of signature 17-
specific peaks after re-running the NMF with signature 17-rich ICGC ESAD data sets listed in 
the Supplementary Materials and Methods section. 
Supplementary Fig. S8: (A) The structures of N7-GA-Gua and N3-GA-Ade adducts analyzed 
by LC-MS/MS. (B) Representative multiple-reaction monitoring chromatograms (relative signal 
intensity vs time) for N7-GA-Gua and N3-GA-Ade adducts in DNA from ACR treatment in the 
presence of S9 fraction (ACR+S9) and GA-treated (GA) primary Hupki MEF. Internal standards 
(IS) were added in amounts of 1000 fmol for N7-GA-Gua and 200 fmol for N3-GA-Ade.  
Supplementary Fig. S9: T:A>A:T enriched mutational signatures used for cosine similarity 
analysis (see Fig. 3D). The individual signatures were originally derived from human cancer 
sequencing data or experimental models (animal bioassays, cell lines) of carcinogen exposure. 
X-axis represents the trinucleotide sequence context. Y-axis represents the frequency 
distribution of the mutations. The predominant trinucleotide context for T:A>A:T mutations is 
indicated by an arrow in the signature landscape. AA: aristolochic acid; DMBA: 7,12-
dimethylbenz[a]anthracene. 
Supplementary Fig. S10: (A) Scatter plots show the measure of correlation of the GA-
signature versus B[a]P-signature (used to reconstruct COSMIC signature 4) in PCAWG lung 
adenocarcinomas (ADCA), lung squamous cell carcinomas (SCC) and hepatocellular 
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carcinomas (HCC). (B) Bar-plots representing the proportion of the assignment of the 
experimental GA_Exp and B[a]P_Exp signatures in lung adenocarcinomas, lung squamous cell 
carcinomas and hepatocellular carcinomas from the PCAWG data set. The asterisk denotes 
liver HCC samples harboring GA-signature only (no B[a]P-signature detected), indicating 
possible dietary or occupational exposure. Full list of these samples is accessible from Suppl. 
Table S5. 
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Supplementary Materials and Methods 
DNA adduct analysis 
The DNA was isolated from the cells using standard digestion with proteinase K, followed by 
phenol-chloroform extraction and ethanol precipitation. The DNA was subsequently treated with 
RNase A and T1, extracted with phenol-chloroform, and reprecipitated with ethanol.  N7 GA-
Gua and N3 GA-Ade were released by neutral thermal hydrolysis for 15 minutes, using 
Eppendorf Thermomixer R (Eppendorf North America) set to 99 °C.  The samples were filtered 
through Amicon 3K molecular weight cutoff filters (Merck Millipore) to separate the adducts from 
the intact DNA. 
 
TP53 genotyping 
The following are the TP53 primers used for amplicon sequencing of mutations accumulated in 
human TP53 of the Hupki MEFs. The sequences are presented in 5’ to 3’ orientation: Exon 4: 
fwd – TGCTCTTTTCACCCATCTAC, rev – ATACGGCCAGGCATTGAAGT; Exons 5-6: fwd – 
TGTTCACTTGTGCCCTGACT, rev – TTAACCCCTCCTCCCAGAGA; Exon 7: fwd – 
CTTGCCACAGGTCTCCCC, rev – CACTTGCCACCCTGCACA; Exon 8: fwd – 
TCCTTACTGCCTCTTGCTTCTCTT; rev – CCAAGGGTGCAGTTATGCCT. Sequences and 
their alterations were analyzed using the CodonCode Aligner software. 
 
Processing of WES data 
Prior to variant calling, recalibrated .bam files were interrogated for imbalanced base mismatch 
distribution  between Read 1 and Read 2 sequences. We used the DNA damage estimator tool 
(as per (1); (https://github.com/Ettwiller/Damage-estimator)) to measure the Global Imbalance 
Value (GIV) score and to exclude sequencing-related DNA damage and artefacts due to 
oxidative damage that can confound the determination of treatment-specific variants. The 
MutSpec suite included tools for annotation of the vcf files with Annovar and variant filtering to 
remove dbSNP142 contents, segmental duplicates, repeats, and tandem repeat regions. 
Finally, to maximize the chance of robust variant calls and to exclude potential unfiltered single 
nucleotide polymorphisms (SNP), we considered only variants unique to each sample.  
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Bioinformatics and statistical analyses  
The following are the International Cancer Genome Consortium (ICGC) esophageal carcinoma 
patient data (2,3) that were used in the step of cleaning the experimental signature from the 
COSMIC signature 17 signal: ESAD-UK-SP119768.hg19; ESAD-UK-SP191660.hg19; ESAD-
UK-SP111113.hg19; ESAD-UK-SP111173.hg19; ESAD-UK-SP192267.hg19; ESAD-UK-
SP111026.hg19; ESAD-UK-SP192494.hg19; ESAD-UK-SP111019.hg19; ESAD-UK-
SP111058.hg19. 
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Abstract 39 
Acrylamide, a probable human carcinogen, is ubiquitously present in the human 40 
environment, with sources including heated starchy foods, coffee and cigarette smoke. 41 
Humans are also exposed to acrylamide occupationally. Acrylamide is genotoxic, inducing 42 
gene mutations and chromosomal aberrations in various experimental settings. Covalent 43 
haemoglobin adducts were reported in acrylamide-exposed humans and DNA adducts in 44 
experimental systems. The carcinogenicity of acrylamide has been attributed to the effects of 45 
glycidamide, its reactive and mutagenic metabolite capable of inducing rodent tumors at 46 
various anatomical sites. In order to characterize the pre-mutagenic DNA lesions and global 47 
mutation spectra induced by acrylamide and glycidamide, we combined DNA-adduct and 48 
whole-exome sequencing analyses in an established exposure-clonal immortalization 49 
system based on mouse embryonic fibroblasts. Sequencing and computational analysis 50 
revealed a unique mutational signature of glycidamide, characterized by predominant 51 
T:A>A:T transversions, followed by T:A>C:G and C:G>A:T mutations exhibiting specific 52 
trinucleotide contexts and significant transcription strand bias. Computational interrogation of 53 
human cancer genome sequencing data indicated that a combination of the glycidamide 54 
signature and an experimental benzo[a]pyrene signature are nearly equivalent to the 55 
COSMIC tobacco-smoking related signature 4 in lung adenocarcinomas and squamous cell 56 
carcinomas. We found a more variable relationship between the glycidamide- and 57 
benzo[a]pyrene-signatures and COSMIC signature 4 in liver cancer, indicating more 58 
complex exposures in the liver. Our study demonstrates that the controlled experimental 59 
characterization of specific genetic damage associated with glycidamide exposure facilitates 60 
identifying corresponding patterns in cancer genome data, thereby underscoring how 61 
mutation signature laboratory experimentation contributes to the elucidation of cancer 62 
causation. 63 
 64 
A 40-word summary  65 
Innovative experimental approaches identify a novel mutational signature of glycidamide, a 66 
metabolite of the probable human carcinogen acrylamide. The results may elucidate the 67 
cancer risks associated with exposure to acrylamide, commonly found in tobacco smoke, 68 
thermally processed foods and beverages.   69 
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Introduction 70 
Cancer can be caused by chemicals, complex mixtures, occupational exposures, physical 71 
agents, and biological agents, as well as lifestyle factors. Many human carcinogens show a 72 
number of characteristics that are shared among carcinogenic agents (1). Different human 73 
carcinogens may exhibit a spectrum of these key characteristics, and operate through 74 
separate mechanisms to generate patterns of genetic alterations. Recognizable patterns of 75 
genetic alterations or mutational signatures characterize carcinogens that are genotoxic. 76 
Recent work shows that these DNA sequence changes can be expressed in simple 77 
mathematical terms that enable mutational signatures to be extracted from thousands of 78 
cancer genome sequencing data sets (2). Several of the over 30 identified mutational 79 
signatures have been attributed to specific external exposures or endogenous factors 80 
through epidemiological and experimental studies (2). However, about 40% of the current 81 
signatures remain of unknown origin, and additional, thus far unrecognized, signatures are 82 
likely to be defined in rapidly accumulating cancer genome data. Well-controlled 83 
experimental exposure systems can thus help identify the underlying causes of known 84 
orphan mutational signatures as well as define new patterns generated by candidate 85 
carcinogens (reviewed in (3,4)). 86 
 Various diet-related exposures contribute to the human cancer burden. Examples 87 
include contaminants in food or alternative medicines, such as aflatoxin B1 (AFB1) or 88 
aristolochic acid (AA). The mutagenicity of these compounds is well-documented; AFB1 89 
induces predominantly C:G>A:T base substitutions and AA causes T:A>A:T transversions. 90 
The characteristic mutations coupled with information on the preferred sequence contexts in 91 
which they are likely to arise allowed unequivocal association of exposure to AFB1 or AA 92 
with specific subtypes of hepatobiliary or urological cancers, respectively (5-13).  93 
 Among dietary compounds with carcinogenic potential, acrylamide is of special 94 
interest due to extensive human exposure. Important sources of exposure to acrylamide 95 
include tobacco smoke (14), coffee (15), and a broad spectrum of occupational settings (16). 96 
Dietary sources of acrylamide comprise carbohydrate-rich food products that have been 97 
subject to heating at high temperatures. This is due to Maillard reactions, which involve 98 
reducing sugars and the amino acid asparagine, present in potatoes and cereals (17). There 99 
is sufficient evidence that acrylamide is carcinogenic in experimental animals (18,19) and it 100 
has been classified as a probable carcinogen (Group 2A) by the International Agency for 101 
Research on Cancer in 1994 (16). The association of dietary acrylamide exposure with 102 
renal, endometrial and ovarian cancers has been explored in recent epidemiological studies 103 
(20,21). However, accurate acrylamide exposure assessment in epidemiological studies 104 
based on questionnaires has been difficult, and more direct measures of molecular markers, 105 
such as hemoglobin adduct levels, may not yield conclusive findings on past exposures (22-106 
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27). An improved understanding of its mechanism of action using well-controlled 107 
experimental systems is critical for understanding the potential carcinogenic risk associated 108 
with exposure. 109 
 Acrylamide undergoes oxidation by cytochrome P450, producing the reactive 110 
metabolite glycidamide that is highly efficient in DNA binding due to its electrophilic epoxide 111 
structure (28-30). The Hras mutation load in neoplasms of mice exposed to acrylamide or 112 
glycidamide was found to be considerably higher in mice treated with glycidamide (31). This 113 
finding is corroborated by a considerably higher mutation frequency in the cII reporter gene 114 
of Big Blue mouse embryonic fibroblasts treated with glycidamide in comparison to 115 
acrylamide (32,33). Mutation analysis in different experimental in vivo and in vitro models 116 
using reporter genes showed an increased association of acrylamide and glycidamide 117 
exposure with T:A>C:G transitions, as well as T:A>A:T and C:G>G:C transversion mutations 118 
(31-36), whereas glycidamide exposure was also characterized by C:G>A:T transversions 119 
(33). However, these proposed acrylamide- and glycidamide-specific mutation patterns were 120 
based on limited mutation counts in reporter genes and thus do not reflect the complexity of 121 
genome-wide distributions and profiles. Based on the limited data available thus far, it is not 122 
possible to translate adequately the reported mutation types (T:A>C:G, T:A>A:T, C:G>G:C, 123 
C:G>A:T) to global alteration patterns.  124 
 The advent of massively parallel sequencing has created the opportunity to study a 125 
large number of mutations in a single sample, thus significantly enhancing the power of 126 
mutation analysis in experimental models and enabling reliable identification of specific 127 
sequence contexts for the induced alterations. Analogously to human cancer genome 128 
projects, genome-scale mutational signatures can be extracted from highly controlled 129 
carcinogen exposure experiments using mammalian cell and animal models coupled with 130 
advanced mathematical approaches (2,3,37,38). 131 
 Here we report the systematic assessment of acrylamide and glycidamide 132 
mutagenicity based on DNA adduct formation and mutation profile analysis using massively 133 
parallel sequencing in a cell model amenable to the analysis of carcinogen-induced mutation 134 
patterns and their impact on the resulting cell phenotype (3,37-39). We identify a specific 135 
and robust mutational signature attributable to glycidamide, and by computationally 136 
interrogating human cancer genome-wide mutation data, we characterize glycidamide 137 
signature-positive tumors, thereby highlighting a potential contribution of 138 
acrylamide/glycidamide exposure to carcinogenesis in humans. 139 
 140 
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Materials and methods 141 
Source and authentication of primary cells 142 
Primary Human-p53 knock-in mouse embryonic fibroblasts (Hupki MEFs) were isolated from 143 
13.5-day old Trp53tm/Holl mouse embryos from the Central Animal Laboratory of the 144 
Deutsches Krebsforschungszentrum, Heidelberg, as described previously (40). The mice 145 
had been tested for Specific Pathogen-Free (SPF) status. The derived primary cells were 146 
genotyped for the human TP53 codon 72 polymorphism (Table 1) to authenticate the 147 
embryo of origin. Cells from three different embryos (E210, E213 and E214) were used for 148 
the exposure experiments (Table 1). All subsequent cell cultures were routinely tested at all 149 
stages for the absence of mycoplasma. 150 
 151 
Cell culture, exposure and immortalization 152 
The primary MEF cells were expanded in Advanced DMEM supplemented with 15% fetal 153 
calf serum, 1% penicillin/streptomycin, 1% pyruvate, 1% glutamine, and 0.1% β-mercapto-154 
ethanol. The cells were then seeded in six-well plates and, at passage 2, exposed for 24 155 
hours to acrylamide (A4058, Sigma), glycidamide (04704, Sigma), or vehicle (PBS). 156 
Acrylamide exposure was carried out in the absence or presence of 2% human S9 fraction 157 
(Life Technologies) complemented with NADPH (Sigma). Exposed and control primary cells 158 
were cultivated until they bypassed senescence and immortalized clonal cell populations 159 
could be isolated (41). The human mammary epithelial cell (HMEC) cultures utilized in this 160 
study for whole-genome sequencing (WGS) were generated from benzo[a]pyrene (B[a]P) 161 
exposed HMEC described previously (42,43). 162 
 163 
MTT assay for cell metabolic activity and viability 164 
Cells were seeded in 96-well plates and treated as indicated. Cell viability was measured 48 165 
hours after treatment cessation using CellTiter 96® Aqueous One solution Cell Proliferation 166 
Assay (Promega). Plates were incubated for 4 hours at 37°C and absorbance was 167 
measured at 492 nm using the APOLLO 11 LB913 plate reader. The MTT assay was 168 
performed in triplicates for each experimental condition. 169 
 170 
γH2Ax Immunofluorescence 171 
Immunofluorescence staining was carried out using an antibody specific for Ser139-172 
phosphorylated H2Ax (γH2Ax) (9718, Cell Signaling Technology). Primary MEFs were 173 
seeded on coverslips in 12 well-plates. The cells were incubated in with γH2Ax-antibody 174 
(1:500 in 1% BSA) at 4°C overnight. Subsequent incubation with a fluorochrome-conjugated 175 
secondary antibody (4412, Cell Signaling Technology) was carried out for 60 minutes at 176 
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room temperature. Coverslips were mounted in Vectashield mounting medium with DAPI 177 
(Eurobio). Immunofluorescence images were captured using a Nikon Eclipse Ti. 178 
 179 
DNA adduct analysis 180 
Glycidamide-DNA adducts (N7-(2-carbamoy-2-hydroxyethyl)-guanine (N7-GA-Gua) and N3-181 
(2-carbamoy-2-hydroxyethyl)-adenine (N3-GA-Ade)) were quantified by liquid 182 
chromatography-mass spectrometry (LC-MS/MS) with stable isotope dilution as previously 183 
described (44) (see Supplementary Materials and Methods for details). The LC-MS/MS used 184 
for quantification consisted of an Acquity UPLC system (Waters) and a Xevo TQ-S triple 185 
quadrupole mass spectrometer (Waters). The same MRM transitions as previously 186 
described (44) were monitored with a cone voltage of 50V and collision energy of 20eV for 187 
each adduct transition and its corresponding labeled isotope transition. 188 
 189 
TP53 genotyping 190 
Exons 4 to 8 of the knocked-in human TP53 gene (NC_000017.11) were sequenced using 191 
standard protocols. Sanger sequencing of PCR products was performed at Biofidal (Lyon, 192 
France). TP53 primer sequences are listed in Supplementary Materials and Methods. 193 
Resulting sequences were analyzed using the CodonCode Aligner software. 194 
 195 
Library preparation and whole-exome sequencing (WES)  196 
Library preparation was carried out using the Kapa Hyper Plus library preparation kit (Kapa 197 
Biosystems) according the manufacturer’s instructions. Exome capture was performed using 198 
the SureSelect XT Mouse All Exon Kit (Agilent Technologies). Eighteen exome-captured 199 
libraries were sequenced in the paired-end 150 base-pair run mode using the Illumina 200 
HiSeq4000 sequencer.  201 
 202 
Processing of WES data  203 
Fastq files were analyzed for data amount and quality using FastQC (0.11.3) and were 204 
processed with an in-house pipeline for adapter trimming and alignment to the mm10 205 
genome (release GRCm38). These components of the pipeline are publicly available at 206 
https://github.com/IARCbioinfo/alignment-nf. The resulting alignment files had a mean depth-207 
of-coverage of 135 and 175 for acrylamide and glycidamide samples, respectively. All 208 
alignment files can be accessed from the NCBI Sequence Read Archive (SRA) data portal 209 
under the BioProject accession number PRJNA238303. Two somatic variant callers were 210 
employed with default parameters in order to detect single base substitutions (SBS) and 211 
small insertions/deletions (indels) (MuTect 1.1.6-4 and Strelka 1.015) in exposed clones, 212 
using primary cells as normal samples. Each immortalized clone was compared to primary 213 
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MEFs from three different embryos (conditions Prim_1, Prim_2, and Prim_3). The overlap of 214 
the variant calling outcome with respect to the different primary MEFs showed concordance 215 
close to 80% (Suppl. Fig. S1) with MuTect exhibiting more stringent calling performance. 216 
Thus, mutation data obtained from the MuTect variant caller were further processed with the 217 
MutSpec suite ((45); https://github.com/IARCbioinfo/mutspec). For more details, see 218 
Supplementary Materials and Methods and the summary of sequencing metrics (Suppl. 219 
Table S1), the list of identified MuTect SBS variants (Suppl. Table S2) and indels (Suppl. 220 
Table S3).  221 
 222 
Bioinformatics and statistical analyses  223 
The FactoMiner R package (R package version 3.3.2; https://cran.r-224 
project.org/web/packages/FactoMineR) was used to perform the principal component 225 
analysis (PCA). To perform the transcription strand bias (SB) analyses, p-values were 226 
calculated using Pearson’s χ2 test. As multiple comparisons were assessed, the p-value 227 
was adjusted by applying a false discovery rate (FDR). Statistical analyses were carried out 228 
using the stats R package. The SB was considered statistically significant at p-value ≤ 0.05. 229 
To analyze samples mutation spectra and treatment-specific mutational signatures, filtered 230 
mutations were classified into 96 types corresponding to the six possible base substitutions 231 
(C:G>A:T, C:G>G:C, C:G>T:A, T:A>A:T, T:A>C:G, T:A>G:C) and the 16 combinations of 232 
flanking nucleotides immediately 5’ and 3’ of the mutated base. Mutation patterns were then 233 
deconvoluted into mutational signatures using the non-negative matrix factorization (NMF) 234 
algorithm (46,47). The reconstruction error calculation evaluated the accuracy with which the 235 
deciphered mutational signatures describe the original mutation spectra of each sample by 236 
applying Pearson correlation and cosine similarity.  237 
 In order to clean up the profile of the glycidamide mutational signature from the 238 
residual signature 17 signal and to increase the stability of NMF decomposition, we supplied 239 
the NMF input by adding samples with a high level of signature 17 (over 65% contribution as 240 
determined by independent NMF analysis, see Supplementary Materials and Methods).  241 
 Cosine similarity analysis was used to evaluate the concordance of the newly 242 
identified T:A>A:T-rich mutational signature of glycidamide with the previously reported 243 
mutational signatures characterized by a predominant T:A>A:T content. These comprised 244 
COSMIC signatures 22 (AA), 25 and 27 (both of unknown etiology(2)), the experimentally 245 
derived mutational signature of AA (37,45), 7,12-dimethylbenz[a]anthracene (DMBA) 246 
(48,49), and urethane (50). 247 
 We employed the mutational signature activity (mSigAct) software’s sparse signature 248 
assignment function (sparse.assign.activity) (13) to assess the presence of the experimental 249 
mutational signatures of glycidamide and benzo[a]pyrene in whole-genome somatic mutation 250 
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data from 38 lung adenocarcinomas, 48 lung squamous carcinomas, and 320 liver cancers 251 
from the ICGC Pan-Cancer Analysis of Whole Genomes (PCAWG) study. We excluded 244 252 
hyper-mutated microsatellite unstable and aristolochic acid signature-containing liver tumors 253 
as the presence of high numbers of T>A mutations adversely prevented assessment of the 254 
possible presence of the glycidamide signature. A set of 11 active COSMIC mutational 255 
signatures were identified in the remaining tumor samples (excluding COSMIC signature 4). 256 
We defined a ‘pure’ experimental C>N benzo[a]pyrene signature by WGS (using 257 
Illumina HiSeq4000 by Genewiz, NJ, USA) of finite lifespan post-stasis clones derived from 258 
primary human mammary epithelial cells (HMEC) treated with B[a]P as previously described 259 
(42,43,51). The read alignment to NCBI GRCh38 genome build, variant calling, filtering and 260 
annotation were consistent with the MutSpec pipeline described above (45). Proportion 261 
matrices of the experimental GA-signature, the GA-signature normalized to the human 262 
genome trinucleotide frequency to allow for human PCAWG data screening, and the whole-263 
genome B[a]P signature are available in Suppl. Table S4. 264 
Results 265 
Acrylamide and glycidamide induce cytotoxic and genotoxic responses in Hupki 266 
MEFs 267 
Upon exposure of primary Hupki MEFs to a range of concentrations of acrylamide (ACR) (in 268 
the absence or presence of the S9 fraction) and its metabolite, glycidamide (GA), we 269 
observed a dose-dependent cytotoxic effect on the cells for either compound (Fig. 1A). This 270 
analysis informed the selection of two conditions for the ACR exposure to be used in the 271 
subsequent exposure/immortalization experiments, 10 mM ACR for 24 hours in the absence 272 
of human S9 fraction, and 5 mM ACR for 24 hours in the presence of S9 fraction, which 273 
elicited 50% (range 30-70%) decrease in cell viability. The IC50 condition for GA was used 274 
for subsequent mutagenesis analysis, corresponding to a 24-hour treatment with 3 mM of 275 
the compound. The genotoxic effects of either ACR or GA manifested by a marked increase 276 
in γH2Ax staining in the exposed cell populations, in comparison to the mock-treated control 277 
cells (Fig. 1B). 278 
 279 
Immortalized MEF cells accumulate TP53 mutations following acrylamide or 280 
glycidamide treatment  281 
Primary MEF cultures from three different embryos (Prim_1, Prim_2, and Prim_3) were 282 
exposed to ACR or GA using the established conditions and multiple immortalized clones 283 
were derived. MEF senescence and immortalization phases were evident from the growth 284 
curves generated for each culture (Suppl. Fig. S2). Subsequently, the clones derived from 285 
ACR exposure (ACR clones) and GA exposure (GA clones) and spontaneous 286 
Page 51 of 62 Carcinogenesis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
9 
 
immortalization (Spont), were pre-screened for TP53 mutations by Sanger sequencing, to 287 
assess the mutagenic process prior to exome-scale analysis. In the context of ACR 288 
treatment, clones obtained from the Prim_2 MEFs that were heterozygous for the 289 
polymorphic site in codon 72 showed a loss of heterozygosity involving a loss of the proline 290 
allele in the ACR_1 clone whereas the arginine allele was lost in ACR_2, giving rise to a 291 
hemizygous clone (Table 1). No TP53 mutations were observed in any of the three Spont 292 
clones, whereas 3 out of 7 ACR clones and 1 of 5 GA clones carried non-synonymous TP53 293 
mutations (Table 1). The detected mutations indicated specific selection for mutations in the 294 
TP53 gene during cell immortalization and confirmed the clonal nature of MEF 295 
immortalization. 296 
 297 
Analysis of mutation spectra 298 
Whole-exome sequencing of all spontaneously immortalized and exposed clones and 299 
subsequent extraction of acquired variants revealed that the total number of acquired SBS 300 
did not differ markedly between the ACR and Spont clones. The Spont clones harbored on 301 
average 190 (median = 151, range = 141-277) SBS, whereas the ACR clones had on 302 
average 208 (median = 173, range = 151-262) SBS. In contrast, the total number of SBS 303 
was considerably increased in the GA clones, with an average of 485 SBS (median = 448, 304 
range = 370-592) (Suppl. Table S1 and S2). This finding suggests markedly stronger 305 
mutagenic properties of GA in the MEFs. To estimate the extent of sequencing-related 306 
damage in our samples, we determined the GIV score of each sample as described in 307 
Materials and Methods and in (52). No detectable damage for any of the mutation types was 308 
observed in our dataset (data not shown). The ACR exposed samples exhibited an overall 309 
diffuse pattern across the six different SBS types (Suppl. Fig. S3). The Spont clones showed 310 
an enrichment of C:G>G:C SBS in the 5’-GCC-3’ context, which was also present at varying 311 
levels in the exposed cultures. This particular mutation type appears to be related to the 312 
culture conditions used for the immortalization assay, as its presence has previously been 313 
noted upon spontaneous as well as exposure-driven MEF immortalization (37). No 314 
significant transcription strand bias was observed for any of the mutation classes in the 315 
Spont or ACR clones (Suppl. Fig. S4). In the five clones derived from the GA-treated primary 316 
MEF cultures, we observed an enrichment of acquired T:A>A:T and C:G>A:T transversions 317 
and T:A>C:G transitions (Suppl. Fig. S3B), marked by significant transcription strand bias 318 
(Suppl. Fig. S4).  319 
 PCA performed on the resulting 6-class SBS spectra unambiguously separated the 320 
GA clones from the remaining experimental conditions (Fig. 2A). The analysis of indels 321 
(listed in Suppl. Table S3) showed lower numbers of these alterations in the GA-associated 322 
clones compared to the ACR or Spont clones (Fig. 2B). This suggests that a higher 323 
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accumulation of SBS may selectively promote the senescence bypass and selection of the 324 
GA clones, with a decreased functional contribution of indels, while an inverse scenario is 325 
plausible in case of the Spont and ACR clones, reminiscent of a previous report based on 326 
the Big Blue mouse embryonic fibroblasts and cII transgene (53).  327 
 328 
Variant allele frequency analysis 329 
Variant allele frequency (VAF) analysis was carried out for GA clones. Overall, a significant 330 
proportion of acquired mutations was present at allelic frequencies between 25-75% (Suppl. 331 
Fig. S5). Upon grouping of substitutions into bins of high (67-100%), medium (34-66%) and 332 
low (0-33%) VAF, the predominant GA-specific mutation types (T:A>A:T, T:A>C:G and 333 
C:G>A:T) started manifesting at high VAF, whereas the 5’-NTT-3’ alterations, corresponding 334 
to the COSMIC signature 17 previously reported to arise in cultured mouse cells including 335 
MEFs (38,54,55) showed lower VAF, therefore a later appearance in the cultures (Suppl. 336 
Fig. S6). This observation suggests the early effects of the GA exposure and the 337 
reproducible contribution of the induced mutations to the senescence bypass and their clonal 338 
propagation during the immortalization stage. 339 
 340 
Mutational signature analysis 341 
Using NMF, we extracted the mutational signatures from all the MEF clones. Using 342 
computed statistics for estimating the number of signatures, three signatures were identified 343 
as an optimal number, with signatures A and C enriched in the Spont and ACR clones, and 344 
signature B selectively enriched in the GA clones (Fig. 2C,D). Reconstruction of the 345 
observed mutation spectra supports the robustness of the signature analysis with strong 346 
Pearson’s correlation and cosine similarity in GA-derived clones (Fig. 2D). In signature C 347 
and also to a lesser extent in signatures A and B, we observed an admixture of a pattern 348 
identical to the orphan COSMIC signature 17 (T:A>G:C in a 5’-NTT-3’ trinucleotide context), 349 
described in various human cancers (most notably esophageal adenocarcinoma), but also 350 
seen in aflatoxin B1-driven mouse liver cancers (11), as well as primary MEF-derived clones 351 
(37,38). In in vitro contexts, this signature has been linked to cell culture conditions and 352 
associated oxidative stress (54,55). To refine further the obtained experimental signatures, 353 
we developed a signature ‘baiting’ approach that combined the MEF clones data with 354 
signature 17-rich data from esophageal adenocarcinomas from the ICGC ESAD-UK study 355 
for new NMF analysis (56). This resulted in considerable reduction (average = 47%, median 356 
= 48%) of the signature 17-specific most prominent T>G peaks and a more refined pattern 357 
for signature B, associated primarily with GA treatment (Fig. 3A and Suppl. Fig. S7). This 358 
putative GA signature retains the predominant enrichment for the T:A>A:T transversions and 359 
T:A>C:G transitions in the 5’-CTG-3’ and 5’-CTT-3’ trinucleotide contexts, and the C:G>A:T 360 
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component. Moreover, these mutation types were marked by significant transcription strand 361 
bias (Fig. 3B and Suppl. Fig. S4), exhibiting higher accumulation of mutations on the non-362 
transcribed strand consistent with the decreased efficiency of the transcription-coupled 363 
nucleotide excision repair due to adduct formation. 364 
 365 
DNA adduct analysis 366 
Following metabolic activation, acrylamide induces well-characterized glycidamide DNA 367 
adducts at the N7- and N3-positions of guanine and adenine, respectively. LC-MS/MS-based 368 
adduct quantification revealed the absence of these adducts in the spontaneously 369 
immortalized control samples as well as in MEFs exposed to acrylamide in the absence of 370 
S9 fraction (levels below the limit of detection). This suggests the lack of CYP2E1 activity, 371 
which is required for the metabolism of acrylamide to glycidamide, in the MEFs. Upon 372 
addition of human S9 fraction, N7-GA-Gua levels increased to 11adducts/108 nucleotides, 373 
suggesting limited metabolic activation of acrylamide due to the presence of enzymatic 374 
activity in the S9 fraction (Fig. 3C and Suppl. Fig. S8). Glycidamide-exposed cells exhibited 375 
significantly increased DNA adduct levels, with both N7-GA-Gua and N3-GA-Ade observed 376 
at very high average levels, 49 000 adducts/108 nucleotides and 350 adducts/108 377 
nucleotides, respectively, after subtracting the trace amount of contamination from the 378 
internal standard (Fig. 3C and Suppl. Fig. S8). 379 
 380 
Comparison of the glycidamide signature to known signatures characterized by 381 
prominent T:A>A:T profiles  382 
We next performed cosine similarity analysis of the putative GA signature and all known 383 
T:A>A:T-rich signatures extracted from primary cancers as well as experimental systems 384 
(Fig. 3D and Suppl. Fig. S9). The best match was 84% pattern similarity with COSMIC 385 
signature 25 (derived from four Hodgkin lymphoma cell lines) (Fig. 3D). However, unlike the 386 
GA signature, COSMIC signature 25 exhibits strand bias for only T:A>A:T mutations and no 387 
transcription strand bias for the T:A>C:G mutations. Thus, the mutation patterns and strand 388 
bias on all three main mutation types generated by GA treatment (Fig. 3A,B) appear specific 389 
and novel. 390 
 391 
Glycidamide signature screening in human tumor data from the ICGC PCAWG 392 
The initial mSigAct test performed on PCAWG data from lung and liver tumors indicated a 393 
marked presence of the GA signature. This observation was in keeping with the presence of 394 
acrylamide in tobacco smoke and was further corroborated by a cosine similarity of 94% 395 
between the adenine (T>N) components of COSMIC signature 4 (tobacco smoking) and the 396 
GA signature (Fig. 4A). We thus hypothesized that COSMIC signature 4 reflects co-397 
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exposure to B[a]P (generating C>N/guanine mutations with transcription strand bias) and to 398 
GA (generating T>N/adenine mutations with transcription strand bias) (Fig. 4A,B). To 399 
provide further experimental evidence, we generated a ‘pure’ B[a]P mutational signature by 400 
whole-genome sequencing of cell clones derived from B[a]P-exposed normal human 401 
mammary epithelial cells (HMEC). This yielded a robust signature characterized by 402 
predominant strand biased guanine (mainly C>A) mutation levels and negligibly mutated 403 
adenines (T>N) (Fig. 4A,B). Next, we used mSigAct to interrogate the PCAWG tumor 404 
samples for the level of exposure to the experimentally defined GA and B[a]P signatures 405 
(alongside other COSMIC mutational signatures) in 48 lung squamous carcinomas, 38 lung 406 
adenocarcinomas, and 320 liver cancers. We compared these to estimated levels of 407 
exposure to COSMIC signature 4, and found that in the lung cancers, a combination of the 408 
GA and B[a]P signatures accounted for very similar numbers of mutations as COSMIC 409 
signature 4, thus further supporting the hypothesis that COSMIC signature 4 represents 410 
combined and highly correlated exposure to GA and B[a]P (Fig. 4C). Compared to lung 411 
cancers, we found more variability in the assignment of mutation numbers to GA and B[a]P 412 
versus COSMIC signature 4 in liver cancers (Fig. 4C), which may reflect a decreased 413 
relationship between GA and B[a]P exposure due to generally more complex exposure 414 
history in the liver. The successful reconstruction of COSMIC signature 4 by the 415 
experimental GA- and B[a]P- signatures in the lung and liver human tumors enabled correct 416 
assignment of the GA-signature in a subset of 29 lung adenocarcinomas, 46 lung SCC and 417 
26 liver tumors (Fig. 4D). The SBS counts corresponding to GA-mutational signature ranged 418 
between 300 up to 43,000 mutations/per sample in lung tumors, and between 190 to 23,000 419 
mutations/per sample in liver tumors (Fig. 4D and Suppl. Table S5). These findings indicate 420 
exposure to glycidamide linked to tobacco smoking – when concomitant with B[a]P-421 
signature, or through diet or occupation – in the absence of B[a]P signature (samples Liver-422 
HCC::SP112224; Liver-HCC::SP49551; Liver-HCC::SP50105; Liver-HCC::SP98861; Liver-423 
HCC::SP50183, see Suppl. Fig. S10 and Suppl. Table S5). 424 
Discussion 425 
In this study we report the identification of an exome-wide mutational signature for 426 
glycidamide, a metabolite of the probable human carcinogen acrylamide. The newly 427 
identified signature is based on massively parallel sequencing performed in a well-controlled 428 
experimental carcinogen exposure-clonal immortalization model, revealing characteristic 429 
mutagenic effects of glycidamide. The glycidamide mutational signature presented here and 430 
the results of statistical assessment of its presence in multiple human tumor types may help 431 
clarify the thus-far tenuous association of acrylamide with human cancer.  432 
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 In concordance with its in vivo carcinogenicity in rodents (16,19,31,57), our findings 433 
in the established MEF carcinogen exposure and immortalization system suggest that 434 
characteristic mutagenic effects may play a role during acrylamide/glycidamide-driven tumor 435 
development. In contrast to glycidamide, acrylamide exposure led neither to an increased 436 
number of SBS nor did it induce characteristic mutation types in the MEF exposure system. 437 
Despite the absence of a mutagenic effect of acrylamide in our experiments, acrylamide and 438 
glycidamide exposures induce an almost identical set of tumors in both mice and rats, 439 
providing a substantial argument for a glycidamide-mediated tumorigenic effect of 440 
acrylamide (19). This is further supported by mechanistic studies showing that lung tissue 441 
from mice exposed to acrylamide and glycidamide displays comparable DNA adduct 442 
patterns as well as similar mutation frequencies in the cII transgene (36). Similar 443 
observations had been made in the context of in vitro mutagenicity of acrylamide in human 444 
and mouse cells, suggesting the key role for epoxide metabolite glycidamide to form pre-445 
mutagenic DNA adducts (33). 446 
 As shown by our adduct analysis, acrylamide is not efficiently metabolized by MEFs. 447 
This finding is in keeping with the results from previous animal carcinogenicity studies. In 448 
fact, glycidamide induces hepatocellular carcinomas in neonatal B6C3F1 mice, whereas 449 
administration of acrylamide does not increase the tumor incidence. This has been attributed 450 
to the inability of neonatal mice to efficiently metabolize acrylamide (31). Moreover, in 451 
contrast to acrylamide treatment, glycidamide induces tumors of the small intestine in a 452 
dose-dependent manner upon perinatal exposure (57) and similar observations were made 453 
for glycidamide mutagenicity in vitro (33). We compensated for the lack of proper acrylamide 454 
metabolic activation by the addition of human S9 fraction, and the assessment of DNA 455 
adducts indeed suggests acrylamide metabolic activation upon addition of S9. However, the 456 
adduct levels are substantially lower compared to glycidamide exposure, which may account 457 
for the observed differences in mutagenicity. Interestingly, a consistent minor contribution of 458 
the glycidamide mutational signature was detected in the majority of ACR clones, whereas it 459 
was absent in the Spont clones. This raises the possibility that partial metabolic activation of 460 
acrylamide in the MEF system resulted in low levels of glycidamide. However, a clear 461 
mutational signature in the employed experimental setting was achieved only by exposing 462 
the cells directly to glycidamide. 463 
Single reporter gene studies had previously linked acrylamide and glycidamide 464 
exposure to multiple different mutation types. Thanks to the larger number of mutations 465 
captured by exome sequencing, we were able to attribute to the glycidamide exposure a 466 
particular mutational signature characterized by strand-biased C:G>A:T and T:A>A:T 467 
transversions, and T:A>C:A transitions towards the non-transcribed strand suggesting a 468 
formation of DNA-adducts. The presence of N7-GA-Gua and N3-GA-Ade, two well-469 
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characterized glycidamide DNA adducts originating from the metabolic conversion of 470 
acrylamide (30,44,53), shows a remarkable relationship between DNA adduct profiles and 471 
the putative mutational signature of glycidamide. N3-GA-Ade and N7-GA-Gua are 472 
depurinating adducts. They can result in apurinic/apyrimidinic sites, which, during replication, 473 
induce the mis-incorporation of deoxyadenine, leading to the observed T:A>A:T and 474 
C:G>A:T transversions of the glycidamide signature, respectively. The third mutation type 475 
specifically enriched in the glycidamide signature, T:A>C:G transitions, has been ascribed to 476 
the N1-GA-Ade adduct, a miscoding adduct and the most commonly identified adenine 477 
adduct in vitro (35,44,53,58). Levels of the guanine adduct were especially high in the 478 
exposed MEF cells, whereas the associated C:G>A:T transversions in the resulting post-479 
senescence clones were less represented. This could reflect differences in DNA repair 480 
efficiency concerning individual GA-DNA adduct species, or the fact that the resulting clones 481 
are derived from single cells whereas the GA-DNA adducts were measured on average in 482 
the bulk primary cell population. A mechanism of negative selection of cells with high N7-483 
GA-Gua adduct burden is also plausible.  484 
We observed consistent presence of COSMIC signature 17 in the data generated 485 
from the untreated and treated MEF clones. The etiology of signature 17 remains unknown. 486 
While some candidate causal factors have been proposed in esophageal adenocarcinoma 487 
and gastric cancers (e.g., inflammatory conditions due to acid reflux, H. pylori) (56) and in 488 
cultured mouse cell systems (54,55), further studies are required to establish why signature 489 
17 tends to arise in vitro in immortalized clones derived from mouse embryonic fibroblasts as 490 
observed in our study and also previous work (38).  491 
 Genome-scale sequencing of tumor tissues will be needed to verify, in vivo, the 492 
glycidamide mutational signature identified in this study. The established animal models 493 
(18,19) of acrylamide- and glycidamide-mediated tumorigenesis provide a suitable starting 494 
point, and it would be interesting to compare mutational signatures derived from these 495 
models with the in vitro results. The identified glycidamide signature with its extended 496 
features of transcription strand bias for the major mutation types differs from the currently 497 
known COSMIC signatures (Fig. 3D). In addition, we show that in the cancer genome 498 
sequencing data sets from the ICGC PCAWG effort, the putative glycidamide-mutational 499 
signature can be identified in a subset of tumors of the lung and liver (sites of possible 500 
acrylamide exposure due to tobacco smoking), based on combining experimentally derived 501 
signatures with sophisticated computational signature reconstruction approaches (Fig. 4). 502 
 The continued interest in understanding the contribution of acrylamide and its 503 
electrophilic metabolite glycidamide to cancer development reflects recent accumulation of 504 
new mechanistic data on the animal carcinogenicity of the compounds. The possible 505 
carcinogenic effects in humans have been recommended for re-evaluation by the Advisory 506 
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Group to the Monographs Program of the International Agency for Research on Cancer (59). 507 
Our findings related to the reconstruction of COSMIC signature 4 using the experimental 508 
GA-signature and B[a]P signature, together with the presence of the GA signature in the 509 
lung and liver cancer data are relevant given the established high contents of acrylamide in 510 
tobacco smoke. Despite the absence of prominent T>N (adenine) mutations in the 511 
experimental B[a]P exposure setting, we cannot exclude a possibility that in the human lung 512 
cells the adenine residues can be additionally targeted by other tobacco carcinogens such 513 
as benzo[a]pyrene derivatives or nitrosamines. Importantly, five liver tumor samples 514 
identified in this study harbored the GA signature but the major features of signature 4 as 515 
represented by the experimental B[a]P signature were absent (Suppl. Fig. S10, Suppl. Table 516 
S5). These tumors are thus of particular interest as they could reflect dietary or occupational 517 
exposure to acrylamide.  518 
 The presented mutational signature of glycidamide and its potential use for screening 519 
of cancer genome sequencing data may provide a basis for relevant assessment of cancer 520 
risk through new carefully designed molecular cancer epidemiology studies. Future 521 
validation analyses involving e.g. GA-DNA adduct monitoring in non-tumor tissue of cancer 522 
patients or in animal exposure models are warranted to provide additional evidence that the 523 
predominant T>N mutations in the cancers identified in this study indeed originate from 524 
exposure to acrylamide and its reactive metabolite glycidamide. 525 
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 690 
Figure legends 691 
Figure 1: Acrylamide- and glycidamide-induced cytotoxicity and genotoxicity in vitro. (A) Cell 692 
viability, following 24-hour treatment of primary MEFs with the indicated concentrations of 693 
acrylamide (top panel), in the absence (diamonds) and presence (circles) of human S9 694 
fraction, and glycidamide (bottom panel), as determined by MTT assay. Absorbance was 695 
measured 48 hours after treatment cessation and was normalized to untreated cells. The 696 
results are expressed as mean percent ±SD of three replicates. (B) DNA damage 697 
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assessment by immunofluorescence with an antibody specific for Ser139-phosphorylated 698 
histone H2Ax (ɣH2Ax). Primary MEFs were treated with acrylamide or glycidamide for 24 699 
hours prior to immunofluorescence. Compound concentrations used were based on 20-70% 700 
viability reduction in the MTT assay: 10 mM acrylamide, 5 mM acrylamide in the presence of 701 
S9 fraction and 3 mM glycidamide. ACR: acrylamide; GA: glycidamide.  702 
Figure 2: Analysis of the mutation patterns derived from exome sequencing data from 703 
immortalized Hupki MEF clones. (A) Principle component analysis (PCA) of WES data. PCA 704 
was computed using as input the mutation count matrix of the clones that immortalized 705 
spontaneously (Spont) or were derived from exposure to acrylamide (ACR) or glycidamide 706 
(GA). Each sample is plotted considering the value of the first and second principal 707 
components (Dim1 and Dim2). The percentage of variance explained by each component is 708 
indicated within brackets on each axis. Spont, ACR- and GA-exposed samples are 709 
represented by differently colored symbols. (B) Representation of small insertions and 710 
deletions (indels) counts within the immortalized clones as determined by the Strelka variant 711 
caller. (C) Mutational signatures identified by non-negative matrix factorization (NMF) in the 712 
15 Hupki MEF-derived clones (sig A, sig B, and sig C). X-axis represents the trinucleotide 713 
sequence context. Y-axis represents the frequency distribution of the mutations. The 714 
predominant trinucleotide context for T:A > A:T mutations is indicated in sig B (5’-CTG-3’). 715 
The trinucleotide contexts for C:G > G:C (5’-GCC-3’) and T:A > G:C mutations (5’-NTT-3’) 716 
are highlighted in sig C. (D) Contribution of the identified signatures to each sample (X-axis), 717 
assigned either by absolute SBS counts or by proportion (bar graphs). The reconstruction 718 
accuracy of the identified mutational signatures in individual samples is shown in the bottom 719 
scatter plot (Y-axis value of 1 = 100% accuracy). 720 
Figure 3: (A) Refinement of GA signature. The contribution of signature 17 (T:A>G:C in 5’-721 
NTT-3’ context), present in all clones, was decreased by performing NMF on Hupki samples 722 
pooled with primary tumor samples with high levels of signature 17 (see Methods). (B) 723 
Transcription strand bias analysis for the six mutation types in GA-exposed clones. For each 724 
mutation type, the number of mutations occurring on the transcribed (T) and non-transcribed 725 
(N) strand is shown on the Y-axis. *** p < 10-8 ; * p < 10-2. (C) DNA adducts analysis as 726 
determined by LC-MS/MS. Levels of N7-GA-Gua adduct in ACR+S9 and GA treated MEFs 727 
and N3-GA-Ade DNA adduct level in GA treated MEFs. The data are presented as the 728 
number of adducts in 108 nucleotides. n ≥ 2. (D) Cosine similarity matrix comparing the 729 
putative glycidamide mutational signature with other A>T rich mutational signatures from 730 
COSMIC (signatures 22, 25, and 27) and from experimental exposure assays using specific 731 
carcinogens (7,12-dimethylbenz[a]anthracene (DMBA), urethane, and aristolochic acid 732 
(AA)).  733 
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Figure 4: GA signature in human primary cancer genome PCAWG data. (A) Comparison of 734 
COSMIC signature 4 with two experimentally derived signatures (B[a]P_Exp = signature in 735 
clones from benzo[a]pyrene treated HMEC cells; GA_Exp = signature in clones from 736 
glycidamide-treated MEF cells). Cosine similarity between the T>N (adenine) components of 737 
signature 4 and GA signature is shown to the right. (B) Transcription strand bias analysis for 738 
the six mutation types underlying the signatures in panel A). For each mutation type, the 739 
number of mutations occurring on the transcribed (T) and non-transcribed (N) strand is 740 
shown on the left Y-axis. The significance is expressed as –log10(p-value) indicated on the 741 
right Y-axis. *** p < 10-8 ; ** p < 10-4 ; * p < 10-2 . (C) Scatter plots show reconstruction of 742 
COSMIC signature 4 using B[a]P- and glycidamide- experimental mutational signatures in 743 
lung adenocarcinoma, lung squamous cell carcinoma and hepatocellular carcinoma from the 744 
PCAWG data set. (D) mSigAct analysis identifies the assignment and the contributions of 745 
mutational signatures (including the experimental signature_GA_Exp (red) and 746 
signature_B[a]P_Exp (blue)) to the mutation burden of a total of 101 PCAWG lung and liver 747 
tumors identified as positive for the GA signature signal. 748 
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